Slammed by more deaths, Seat­tle Ge­net­ics scraps a PhI­II study and pulls back (again) on vadas­tux­imab

Clay Sie­gall

Just three months af­ter the FDA lift­ed a clin­i­cal hold on its late-stage can­cer drug vadas­tux­imab talirine (SGN-CD33A), the biotech abrupt­ly scrapped a Phase III study and halt­ed en­roll­ment across a slate of stud­ies af­ter in­de­pen­dent mon­i­tors tracked a high­er rate of deaths among pa­tients tak­ing its drug.

The deaths in the study — for front­line use against acute myeloid leukemia — in­clud­ed fa­tal in­fec­tions but were ev­i­dent­ly not as­so­ci­at­ed with liv­er tox­i­c­i­ty, which had al­ready killed 4 pa­tients, forc­ing the FDA to hit the brakes on the study in late De­cem­ber, 2016.

The lat­est safe­ty cri­sis will hit Seat­tle Ge­net­ics $SGEN hard. The com­pa­ny had been re­port­ing pos­i­tive da­ta on the drug, its most ad­vanced ex­per­i­men­tal drug in the pipeline, and an­a­lysts were look­ing for new ways for the com­pa­ny to ex­pand be­yond Ad­cetris. Just a few weeks ago Seat­tle Ge­net­ics was al­so forced to throw the tow­el in on a $2 bil­lion deal to col­lab­o­rate with Im­munomedics, fur­ther lim­it­ing its late-stage ef­fort.

The com­pa­ny’s stock dropped 12% on the news, mark­ing the loss of about $1 bil­lion in mar­ket cap.

Da­ta at one point for vadas­tux­imab demon­strat­ed that 15 of 23 (65%) evalu­able pa­tients achieved CR/CRi. At a me­di­an fol­low-up of 7.7 months, me­di­an sur­vival had not yet been reached, and 72 per­cent of pa­tients re­mained alive and on study.

Back in March the biotech re­port­ed that it was get­ting restart­ed on the clin­i­cal work af­ter it came up with “re­vised el­i­gi­bil­i­ty cri­te­ria and stop­ping rules for veno-oc­clu­sive dis­ease.” The FDA agreed to lift the hold on­ly two months af­ter it was dropped on Seat­tle Ge­net­ics. And the agency may face ques­tions about why it was so quick to agree to the green light, giv­en the re­cent deaths.

Seat­tle Ge­net­ics CEO Clay Sie­gall tried to shift the fo­cus to the pos­i­tive. He not­ed:

“We are en­thu­si­as­tic about the many op­por­tu­ni­ties across our broad pipeline, in­clud­ing AD­CETRIS (bren­tux­imab ve­dotin), en­for­tum­ab ve­dotin (ASG-22ME) and SGN-LIV1A. No­tably, we are look­ing for­ward to re­port­ing da­ta from our AD­CETRIS phase 3 ECH­E­LON-1 tri­al in front­line Hodgkin lym­phoma, and we are on track to ad­vance en­for­tum­ab ve­dotin in­to a piv­otal tri­al in metasta­t­ic urothe­lial can­cer in the sec­ond half of 2017 un­der our col­lab­o­ra­tion with Astel­las.”

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

Roger Perlmutter needs no introduction to anyone remotely involved in biopharma. As the R&D chief first at Amgen and then Merck, he’s built a stellar reputation and a prolific career steering new drugs toward the market for everything from cancer to infectious diseases.

But for years, he’s also held a less known title: science partner at The Column Group, where he’s regularly consulted about the various ideas the VCs had for new startups.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ad­comm splits slight­ly in fa­vor of FDA ap­prov­ing Chemo­Cen­tryx’s rare dis­ease drug

The FDA’s Arthritis Advisory Committee on Thursday voted 10 for and 8 against the approval of ChemoCentryx’s $CCXI investigational drug avacopan as a treatment for adults with a rare and serious disease known as anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis.

The vote on whether the FDA should approve the drug was preceded by a split vote of 9 to 9 on whether the efficacy data support approval, and 10 to 8 that the safety profile of avacopan is adequate enough to support approval.

Paul Hastings, Nkarta CEO

With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

Most deals in biotech come with hefty upfront payments attached, and the promise of big biobucks if a program works out. Not this one.

Nkarta has struck what CEO Paul Hastings calls a “real collaboration” with CRISPR Therapeutics to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The duo will split all R&D costs — and any worldwide profits — 50/50, Hastings said.

Brent Saunders (Richard Drew, AP Images)

OcuWho? Star deal­mak­er turned aes­thet­ics czar Brent Saun­ders flips back in­to biotech. But who’s he team­ing up with now?

Brent Saunders went on a tear of headline-blazing deals building Allergan, merging and rearranging a variety of big companies into one before an M&A pact with Pfizer blew up and sent him on a bout of biotech drug deals. That didn’t work so well, so under pressure, he got his buyout at AbbVie — which needed a big franchise like Botox. And it was no big surprise to see him riding the SPAC wave into a recent $1 billion-plus deal that left him in the executive chairman’s seat at an aesthetics outfit — now redubbed The Beauty Health Company — holding a big chunk of the equity.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Drug pric­ing watch­dog joins the cho­rus of crit­ics on Bio­gen's ad­u­canum­ab: What about charg­ing $2,560 per year?

As if Biogen’s aducanumab isn’t controversial enough, the researchers at drug pricing watchdog ICER have drawn up the contours of a new debate: If the therapy does get approved for Alzheimer’s by June, what price should it command?

Their answer: At most $8,290 per year — and perhaps as little as $2,560.

Even at the top of the range, the proposed price is a fraction of the $50,000 that Wall Street has reportedly come to expect (although RBC analyst Brian Abrahams puts the consensus figure at $11.5K). With critics, including experts on the FDA’s advisory committee, making their fierce opposition to aducanumab’s approval loud and clear, the pricing pressure adds one extra wrinkle Biogen CEO Michel Vounatsos doesn’t need as he orders full-steam preparation for a launch.

Biden ad­min­is­tra­tion backs a po­lar­iz­ing pro­pos­al to waive IP for all Covid-19 vac­cines

In a surprise U-turn, the Biden administration said Wednesday that it will support a proposal at the World Trade Organization to temporarily waive intellectual property protections on Covid-19 vaccines.

The proposal, backed by South Africa and India at the WTO, seeks to help developing countries with limited vaccine supplies. The US and Europe historically opposed the proposal, saying IP should be protected because it incentivizes new drug and vaccine development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.